ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs MXN
20.62511
-0.02%
Brent Oil
76.425
-0.10%
Bitcoin
98,547.76
0.25%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Blueprint Medicines Corporation (BPMC)

  7. Blueprint Medicines Corporation (BPMC) Noticias

BPMC

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:BPMC
FechaHoraFuenteTítuloSímboloCompañía
20/12/202415:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
19/12/202416:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
18/12/202415:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPMCBlueprint Medicines Corporation
18/12/202407:00PR Newswire (US)Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
07/12/202411:30PR Newswire (US)Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
12/11/202412:44Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:BPMCBlueprint Medicines Corporation
30/10/202415:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BPMCBlueprint Medicines Corporation
30/10/202406:00PR Newswire (US)Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceNASDAQ:BPMCBlueprint Medicines Corporation
16/10/202407:00PR Newswire (US)Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024NASDAQ:BPMCBlueprint Medicines Corporation
10/09/202407:00PR Newswire (US)Blueprint Medicines to Present at Upcoming Investor ConferencesNASDAQ:BPMCBlueprint Medicines Corporation
01/08/202406:00PR Newswire (US)Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceNASDAQ:BPMCBlueprint Medicines Corporation
18/07/202407:00PR Newswire (US)Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024NASDAQ:BPMCBlueprint Medicines Corporation
30/05/202417:01PR Newswire (US)Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)NASDAQ:BPMCBlueprint Medicines Corporation
23/05/202416:05PR Newswire (US)Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
06/05/202415:01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
02/05/202406:00PR Newswire (US)Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceNASDAQ:BPMCBlueprint Medicines Corporation
18/04/202407:00PR Newswire (US)Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024NASDAQ:BPMCBlueprint Medicines Corporation
11/04/202407:00PR Newswire (US)Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsNASDAQ:BPMCBlueprint Medicines Corporation
23/02/202407:00PR Newswire (US)Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
16/02/202415:40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BPMCBlueprint Medicines Corporation
15/02/202416:26Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BPMCBlueprint Medicines Corporation
15/02/202406:00PR Newswire (US)Blueprint Medicines Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
01/02/202407:00PR Newswire (US)Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024NASDAQ:BPMCBlueprint Medicines Corporation
08/01/202407:00PR Newswire (US)Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
18/12/202307:00PR Newswire (US)Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
12/12/202307:05PR Newswire (US)Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
09/12/202311:30PR Newswire (US)Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
28/11/202307:00PR Newswire (US)Blueprint Medicines to Present at JMP Securities Hematology and Oncology SummitNASDAQ:BPMCBlueprint Medicines Corporation
10/11/202307:00PR Newswire (US)Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic MastocytosisNASDAQ:BPMCBlueprint Medicines Corporation
26/10/202306:00PR Newswire (US)Blueprint Medicines Reports Third Quarter 2023 ResultsNASDAQ:BPMCBlueprint Medicines Corporation
 Showing the most relevant articles for your search:NASDAQ:BPMC

Su Consulta Reciente

NYSE
CVX
Chevron
FX
EURUSD
Euro vs US Dollar
FX
USDMXN
US Dollar vs MXN
COIN
AVAXUSD
Avalanche
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
USOTC
BASFY
BASF (QX)
AMEX
XLV
Health Care Select Sector
CCOM
SILVER
SILVER
COIN
DOGEUSD
Dogecoin
NYSE
JPM
JP Morgan Chase
NYSE
NKE
Nike
CCOM
US500
US 500
SPI
SP500
S&P 500
NYSE
XOM
Exxon Mobil
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados